Shares of Agios Pharmaceuticals Inc. (AGIO) have retreated approximately 43% from their 52-week high of $62.58, reported last November, and trade near the $35 level.
The company's flagship drug, PYRUKYND, has demonstrated strong year-over-year sales growth since its initial approval in February 2022. The drug is currently indicated for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com